We are Sorry, This Page doesn't Exist
Cambridge biotech startup grabs $65M to tackle liver disease
A newly launched biotech company has secured $65 million in financing as it seeks to develop the first-ever treatment for a disorder that its co-founder described as “the life being squeezed out of the liver.” Cambridge-based Akero Therapeutics is fo.....»»
Alzheimer’s Disease Symptoms Reversed in Flies by Balancing Enzymes
This finding could pave the wave for Alzheimer's treatment and biomarkers for early diagnosis......»»
IPO News This Week: Two Solid Offerings on Tap
The two IPOs on this week's calendar include one tech unicorn and a biotech working on a treatment from Alzheimer disease......»»
MGH to study medical device for concussions, Alzheimer"s
Massachusetts General Hospital has begun a four-year research project with a New Jersey-based medical device company looking at concussive brain injuries and Alzheimer’s disease. The company, electroCore, said it is providing MGH with $1 millio.....»»
Make Your Brain ‘Happy’ Eat Real Food
Make Your Brain ‘Happy’ Eat Real Food It is being said by the medical experts that by Y 2020, America will have 14-M people in need of full-time care for Alzheimer’s disease. Anxiety di.....»»
Akari Announces First Quarter 2018 Financial Results and Update on its Growing Pipeline of Phase II and Phase III Clinical Trials
Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve paroxysmal nocturnal hemoglobinuria (PNH), in which patient treatment has commenced Phase II U.S. trial f.....»»
Google Bests Doctors in Eye Disease Treatment
In another sign that artificial intelligence can outthink humans, Google announced it was able to more quickly detect eye disease problems than medical professionals......»»
Amicus Receives First FDA Approval For Fabry Disease Treatment In 15 Years
Amicus Receives First FDA Approval For Fabry Disease Treatment In 15 Years.....»»
FDA Approves $450,000-a-Year Treatment for Rare Disease
Patients who have hereditary transthyretin-mediated amyloidosis, or hATTR, will take the drug for the rest of their lives. Alnylam Phar.....»»
FDA approves Amicus" Galafold for treatment of patients with Fabry Disease
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Ovid Therapeutics shares fall 28% as investors question new drug data (OVID)
Markets Insider New York-based biotech company Ovid Therapeutics announced on Monday positive phase 2 trial results for its treatment for a rare disease called Angelman Syndrom.....»»
Pain Therapeutics has initiated a strategic reorganization to focus on Alzheimer"s treatment
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Brainstorm Health: Alzheimer’s and Elephants, Google and Rehab Ads, Bacteria Hand Sanitizer Resistance
Brainstorm Health Daily: August 3, 2018 Alzheimer's disease research has long been beset by a religious war of sorts: "BAPtists" ardently believe that plaques formed by beta-amyloid protei.....»»
Biogen Results: Time To Change The Paradigm In Alzheimer"s Disease
Biogen Results: Time To Change The Paradigm In Alzheimer"s Disease.....»»
World Leaders Want to End Alzheimer’s by 2025. A New Drug Breakthrough Means We Just Might
New drug suggests you can stop Alzheimer's in its tracks, and reduce symptoms. The quest to effectively diagnose, treat and even prevent A.....»»
Hopes rise again for a drug to slow Alzheimer"s disease
Hopes are rising again for a drug to alter the course of Alzheimer's disease after repeated failures......»»
Alzheimer"s Drug Shows Benefit
Eisai and Biogen revealed new data showing their closely watched experimental drug slowed the worsening of Alzheimer’s disease, but some experts said more testing is needed......»»
Biogen shares rise nearly 4% before release of Alzheimer"s disease trial results
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»
Biogen shares rise 4% before release of Alzheimer"s disease trial results
Biogen Inc. shares rose more than 4%.....»»
Biogen easily tops Street estimates on Spinraza sales, raises forecast
Biogen Inc reported far better-than-expected second quarter profit on Tuesday, driven by strong demand of its Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast......»»